Peptide Encyclopedia / Metabolic signaling
Retatrutide Research
Retatrutide research spans receptor pharmacology and controlled clinical investigation. Understanding that distinction helps readers evaluate a trial without treating its results as a specification for a retail research material.
Research reading guide • Published 24 October 2026 • Selected foundational study
What the selected study examined
A 2023 randomized phase 2 trial studied retatrutide in 338 adults with obesity. The compound was described as an agonist at GIP, GLP-1 and glucagon receptors. The trial reported changes in body weight over its observation period and recorded adverse events. It provides human evidence within a defined trial population, with controlled study material and monitoring. Read the original publication record.
How to read the result
Read the eligibility criteria and participant flow before looking at headline results. Compare prespecified outcomes, discontinuations and the timing of measurements. Determine how missing observations were handled and whether a reported result refers to all randomized participants or a narrower analysis set.
What this evidence does not establish
Results from a monitored clinical trial do not establish the identity, formulation, safety or suitability of material offered elsewhere. A phase 2 result also does not settle longer-term outcomes or every population. This article does not provide a treatment protocol or describe current regulatory status.
A practical research documentation checklist
Before comparing a material with a publication, record its exact name, sequence or chemical form, supplier reference and lot identifier. Ask for the original analytical report and check that the sample identifier matches. Review the method, date and result together; a purity percentage does not answer every identity or suitability question. Keep a record of storage guidance, receipt conditions and any handling deviations relevant to your approved laboratory work.
Questions to ask before citing this research
Does a positive endpoint prove a broad benefit?
No. State the endpoint, model and comparison explicitly. Avoid replacing a measured observation with a larger outcome that was not evaluated.
Does a publication verify a product lot?
No. Scientific literature and batch documentation serve different purposes. Connect each claim to the evidence that actually supports it.
Primary reference
Jastreboff et al. New England Journal of Medicine (2023);389:514–526. DOI: 10.1056/NEJMoa2301972. PubMed: 37366315. This introductory page summarizes a selected study and is not an exhaustive review.
Continue your research
Research use only. Educational information for laboratory research. Not medical advice and not for human or veterinary use. No administration instructions or product-specific testing claims are provided.